Miragen Therapeutics, which holds the rights to the discovery, is interested in seeing the work advance. But a company official said that development of a miRNA-targeting drug for ALS would likely only occur in earnest with a partner.
Originally developed in the lab of Phillip Sharp at the Massachusetts Institute of Technology, miRNA sponges are transcripts expressed from strong promoters that contain multiple tandem binding sites to an miRNA of interest.
Under the deal, InteRNA’s lentiviral-based miRNA over-expression library will be used in “multi-parametric, high-throughput functional screening assays” to identify the role of individual miRNAs in various cancer pathways. The company hopes to discover novel miRNAs as therapeutic targets.